|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WDR55 |
Gene summary for WDR55 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WDR55 | Gene ID | 54853 |
| Gene name | WD repeat domain 55 | |
| Gene Alias | WDR55 | |
| Cytomap | 5q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9H6Y2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54853 | WDR55 | LZE4T | Human | Esophagus | ESCC | 8.89e-04 | 1.11e-01 | 0.0811 |
| 54853 | WDR55 | LZE24T | Human | Esophagus | ESCC | 1.32e-12 | 2.64e-01 | 0.0596 |
| 54853 | WDR55 | P2T-E | Human | Esophagus | ESCC | 4.47e-17 | 1.12e-01 | 0.1177 |
| 54853 | WDR55 | P4T-E | Human | Esophagus | ESCC | 6.31e-08 | 1.82e-01 | 0.1323 |
| 54853 | WDR55 | P5T-E | Human | Esophagus | ESCC | 4.88e-14 | 2.22e-01 | 0.1327 |
| 54853 | WDR55 | P8T-E | Human | Esophagus | ESCC | 2.67e-09 | 7.46e-02 | 0.0889 |
| 54853 | WDR55 | P9T-E | Human | Esophagus | ESCC | 1.03e-06 | 1.43e-01 | 0.1131 |
| 54853 | WDR55 | P10T-E | Human | Esophagus | ESCC | 6.96e-10 | 1.06e-01 | 0.116 |
| 54853 | WDR55 | P11T-E | Human | Esophagus | ESCC | 8.67e-14 | 4.55e-01 | 0.1426 |
| 54853 | WDR55 | P12T-E | Human | Esophagus | ESCC | 1.22e-11 | 2.88e-01 | 0.1122 |
| 54853 | WDR55 | P15T-E | Human | Esophagus | ESCC | 1.17e-09 | 1.26e-01 | 0.1149 |
| 54853 | WDR55 | P16T-E | Human | Esophagus | ESCC | 5.23e-15 | 9.51e-02 | 0.1153 |
| 54853 | WDR55 | P17T-E | Human | Esophagus | ESCC | 3.29e-12 | 2.43e-01 | 0.1278 |
| 54853 | WDR55 | P19T-E | Human | Esophagus | ESCC | 3.41e-03 | 5.00e-01 | 0.1662 |
| 54853 | WDR55 | P20T-E | Human | Esophagus | ESCC | 1.20e-17 | 3.76e-01 | 0.1124 |
| 54853 | WDR55 | P21T-E | Human | Esophagus | ESCC | 6.82e-25 | 3.37e-01 | 0.1617 |
| 54853 | WDR55 | P22T-E | Human | Esophagus | ESCC | 5.96e-13 | 2.12e-01 | 0.1236 |
| 54853 | WDR55 | P23T-E | Human | Esophagus | ESCC | 1.10e-15 | 2.97e-01 | 0.108 |
| 54853 | WDR55 | P24T-E | Human | Esophagus | ESCC | 1.08e-14 | 3.23e-01 | 0.1287 |
| 54853 | WDR55 | P26T-E | Human | Esophagus | ESCC | 2.27e-12 | 1.22e-01 | 0.1276 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:001607212 | Liver | HCC | rRNA metabolic process | 193/7958 | 236/18723 | 1.26e-35 | 1.14e-32 | 193 |
| GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| GO:000636410 | Oral cavity | OSCC | rRNA processing | 172/7305 | 225/18723 | 1.57e-30 | 1.24e-27 | 172 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| GO:001607210 | Oral cavity | OSCC | rRNA metabolic process | 176/7305 | 236/18723 | 6.51e-29 | 3.24e-26 | 176 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
| GO:0042254113 | Thyroid | PTC | ribosome biogenesis | 202/5968 | 299/18723 | 3.47e-37 | 5.47e-34 | 202 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WDR55 | SNV | Missense_Mutation | c.278N>T | p.Ser93Phe | p.S93F | Q9H6Y2 | protein_coding | deleterious(0) | possibly_damaging(0.837) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| WDR55 | insertion | Frame_Shift_Ins | novel | c.742_743insCAACTGGAAAGACGTGTTTCCAAGGCTCATG | p.Arg248ProfsTer17 | p.R248Pfs*17 | Q9H6Y2 | protein_coding | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
| WDR55 | SNV | Missense_Mutation | c.278N>G | p.Ser93Cys | p.S93C | Q9H6Y2 | protein_coding | deleterious(0) | possibly_damaging(0.878) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| WDR55 | SNV | Missense_Mutation | rs557759167 | c.743G>A | p.Arg248His | p.R248H | Q9H6Y2 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WDR55 | SNV | Missense_Mutation | novel | c.542N>C | p.Lys181Thr | p.K181T | Q9H6Y2 | protein_coding | deleterious(0.01) | possibly_damaging(0.703) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WDR55 | SNV | Missense_Mutation | c.973G>A | p.Ala325Thr | p.A325T | Q9H6Y2 | protein_coding | tolerated(0.18) | benign(0.001) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| WDR55 | SNV | Missense_Mutation | rs138378618 | c.1009N>T | p.Arg337Trp | p.R337W | Q9H6Y2 | protein_coding | deleterious(0.02) | benign(0) | TCGA-DC-6160-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| WDR55 | SNV | Missense_Mutation | c.278N>G | p.Ser93Cys | p.S93C | Q9H6Y2 | protein_coding | deleterious(0) | possibly_damaging(0.878) | TCGA-DY-A0XA-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Chemotherapy | mayo | CR | |
| WDR55 | insertion | Frame_Shift_Ins | rs757148941 | c.1014_1015insA | p.Gly343ArgfsTer15 | p.G343Rfs*15 | Q9H6Y2 | protein_coding | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| WDR55 | insertion | Frame_Shift_Ins | novel | c.661_662insG | p.Lys223GlufsTer9 | p.K223Efs*9 | Q9H6Y2 | protein_coding | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |